Status:
RECRUITING
Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine
Lead Sponsor:
Cairo University
Conditions:
Sphenopalatine Block
BOTOX
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This trial compares the efficacy and safety of sphenopalatine ganglion block (SPGB) and intramuscular BOTOX injection in chronic migraine.
Detailed Description
The International Headache Society's Headache Classification Committee recognizes three broad categories of headaches: primary headaches, secondary headaches, and a third catchall category called "pai...
Eligibility Criteria
Inclusion
- Age 18 and 65 years.
- Both sexes.
- Chronic migraine. Chronic migraine, defined as headaches on ≥15 days per month for ≥3 months, of which ≥8 days meet criteria for migraine without aura or respond to migraine-specific treatment according to International Classification of Headache Disorders-3 Beta.
Exclusion
- Patients with medication over use headache.
- Bleeding disorders.
- Abnormal neurological examination.
- History of allergy to local anesthetics or BOTOX.
Key Trial Info
Start Date :
May 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2025
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT06974617
Start Date
May 15 2025
End Date
October 1 2025
Last Update
May 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cairo University
Cairo, Egypt, 12613